Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Interest & Investment Income (2016 - 2025)

Fennec Pharmaceuticals filings provide 15 years of Interest & Investment Income readings, the most recent being $228000.0 for Q4 2025.

  • On a quarterly basis, Interest & Investment Income fell 42.86% to $228000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $787000.0, a 53.21% decrease, with the full-year FY2025 number at $787000.0, down 53.21% from a year prior.
  • Interest & Investment Income hit $228000.0 in Q4 2025 for Fennec Pharmaceuticals, up from $152000.0 in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $570000.0 in Q2 2024 to a low of $9000.0 in Q1 2022.
  • Median Interest & Investment Income over the past 5 years was $115000.0 (2023), compared with a mean of $165631.6.
  • Biggest five-year swings in Interest & Investment Income: soared 1177.78% in 2023 and later plummeted 70.54% in 2025.
  • Fennec Pharmaceuticals' Interest & Investment Income stood at $13000.0 in 2021, then soared by 1084.62% to $154000.0 in 2022, then dropped by 25.32% to $115000.0 in 2023, then skyrocketed by 246.96% to $399000.0 in 2024, then crashed by 42.86% to $228000.0 in 2025.
  • The last three reported values for Interest & Investment Income were $228000.0 (Q4 2025), $152000.0 (Q3 2025), and $171000.0 (Q2 2025) per Business Quant data.